Ox2r-004: Phase 1 Wet-lab — Reference + Stabilised Variant (S1)

OX2R-004-S1 is a stabilised ncAA variant (Ac + D-Arg4 + D-Tyr5) of OX2R-004, designed for ADHD via the orexin pathway and engineered to address the Gate 6 proteolytic-stability flag (predicted serum t1/2 15 to 55 min, cleavage sites 34 to 28). Phase 1 wet-lab tests OX2R-004-S1 against the natural-AA parent OX2R-004 and Orexin-B (native ligand) at Adaptyv (BLI + OX1R counter-screen), with cAMP HTRF at Ginkgo on top binders and plasma-stability LC-MS. Comparative output addresses both the stability and OX1R-selectivity flags from the computational pipeline.